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The most simple and commonly used approach for genetic associations is the case-control study design of unrelated
people. This design is susceptible to population stratification. This problem is obviated in family-based studies, but it is
usually difficult to accumulate large enough samples of well-characterized families. We addressed empirically whether
the two designs give similar estimates of association in 93 investigations where both unrelated case-control and
family-based designs had been employed. Estimated odds ratios differed beyond chance between the two designs in
only four instances (4%). The summary relative odds ratio (ROR) (the ratio of odds ratios obtained from unrelated case-
control and family-based studies) was close to unity (0.96 [95% confidence interval, 0.91–1.01]). There was no
heterogeneity in the ROR across studies (amount of heterogeneity beyond chance I
2 ¼ 0%). Differences on whether
results were nominally statistically significant (p , 0.05) or not with the two designs were common (opposite
classification rates 14% and 17%); this reflected largely differences in power. Conclusions were largely similar in
diverse subgroup analyses. Unrelated case-control and family-based designs give overall similar estimates of
association. We cannot rule out rare large biases or common small biases.
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Introduction
Genetic associations for complex diseases may be probed
either with case-control studies of unrelated people or with
family-based designs. Both designs have advantages and
disadvantages. Studies of cases and unrelated controls are
the most commonly used approach; sufﬁciently large study
populations can be readily assembled without the need to
enroll also family members of the recruited participants.
However, a disadvantage of this approach is that confounding
due to unaccounted population admixture remains a possible
threat to the validity of the obtained results [1–3]. On the
other hand, family-based study designs (e.g. those including
case-sibling pairs or case-parent trios) have the advantage
that there is a common genetic background among the family
members. Thus, the problem of population stratiﬁcation is
bypassed. Moreover, families tend to be more homogeneous
regarding exposure to environmental factors possibly asso-
ciated to the disease etiology. The main disadvantage of
family-based studies, however, is that it is usually more
difﬁcult to accumulate large enough samples of well-
characterized families. Therefore such studies represent the
minority of investigations assessing genetic associations of
complex diseases.
This problem of most appropriate versus most feasible
study design may become even more pressing in the era of
whole-genome strategies. Modest confounding due to pop-
ulation stratiﬁcation may create unacceptable noise in the
search for signiﬁcant associations across the genome. Con-
versely, sample sizes need to be large enough to avoid type I
error both in the screening process, as well as in the
validation of what are likely to be modest genetic effects [4].
Of course, increasing sample size alone is not guaranteed to
control type I error. Association studies, regardless of design,
may be further confounded by genotyping error, misclassi-
ﬁcation of phenotypes and confounding by unmeasured or
poorly measured environmental factors.
Strong views have been expressed on the relative merits of
and preference for family-based versus unrelated controls
designs [2,5]. A number of approaches have been proposed to
try to detect and account for population stratiﬁcation in
population based studies [6–11]. Methods have also been
developed to merge estimates of association from the two
types of design [12,13]. Moreover, in an effort to maximize
efﬁciency, several investigators have also proposed methods
for hybrid designs that utilize data from both types of study
designs [14–16]. Besides theoretical considerations, it would
be interesting to obtain some empirical data on the extent to
which these designs agree or disagree with each other. These
data could be derived from investigations where both types of
study designs were used to answer the same question on a
postulated gene-disease association. We used a meta-analysis
approach, i.e. a systematic selection of data and quantitative
synthesis of results across many studies.
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Eligible Data
We analyzed a total of 93 eligible comparisons between
family-based and unrelated case-control designs where both
designs had been used by the same investigators to address
the same postulated gene-disease association (Table 1, Data-
set S1, Text S1, Figure 1). The median sample size for the
unrelated case-control study was 434 (interquartile range,
280–691), while the median number of transmitted plus non-
transmitted alleles for the family-based studies was 79
(interquartile range, 54–133).
In these 93 comparisons, the populations analyzed in the
family-based and unrelated case-control studies overlapped
(i.e. same individuals included in both family-based and case-
control designs) in 47 and in 16 comparisons it was clearly
stated that this was the ﬁrst published investigation address-
ing the speciﬁc gene-disease association. Moreover, in 25
comparisons, it was clearly stated that one design was applied
ﬁrst (family-based n ¼ 10, unrelated case-control n ¼ 15) and
in 15 comparisons the results for one design had been
selected for presentation based on their own statistical
signiﬁcance (n¼6 [family-based n¼5, unrelated case-control
n ¼ 1]) or the statistical signiﬁcance of the results obtained
with the other design (n ¼ 8 [family-based n ¼ 5, unrelated
case-control n ¼ 3]). Finally, three studies violated Hardy-
Weinberg equilibrium (HWE) assumption (exact test p , 0.05
for the distribution of genotypes in the unrelated controls),
and another two studies had absolute ﬁxation coefﬁcients
exceeding 0.03 in the unrelated controls, even though this
deviation from HWE was not formally signiﬁcant.
Comparison of Genetic Effects with the Two Designs
We combined the odds ratios (OR) in the family-based
design (OR
F) and the unrelated case-control design (OR
U) for
the minor versus major allele in order to obtain a summary
OR for the strength of each probed association. When this
summary OR was ,1, we inversed the allele contrast, so that
all summary ORs would be  1. We then estimated the ratio of
the OR
U over OR
F. This relative odds ratio (ROR) reﬂects the
difference in the effect size between the two designs. It is
expected to be 1 when the two estimates agree, .1 when the
family-based design gives a smaller estimate of association
than the unrelated case-control design, and ,1 when the
opposite occurs. When the 95% conﬁdence interval (CI) for
ROR does not contain 1, then the difference between OR
F
and OR
U is beyond chance at the 0.05 level of signiﬁcance.
The difference between these two estimates was signiﬁcant
only in four (4%) probed associations (Figure 1). An
evaluation of the MLC1 rs2076127 G/A polymorphism, found
a strong association with schizophrenia in the family-based
design, but no effect in the unrelated case-control design [17];
the same scenario was seen for the putative association of
CRTH2 (G1544C) with asthma [18] and for the putative
association of 5q31 C2063G with Crohn disease [19].
Conversely, an evaluation of the DBH (TaqI) polymorphism
and attention deﬁcit hyperactivity disorder persisting into
adulthood found a borderline signiﬁcant association in the
unrelated case-control design, but no signiﬁcant association
with the family-based design [20]. We perused PubMed to
examine whether for these four postulated associations any
additional studies had been published with larger sample size
for the respective study design. We did not ﬁnd any larger
studies for the exact speciﬁc polymorphisms and with exactly
the same phenotype. Interestingly, for DBH and attention
deﬁcit hyperactivity disorder, three previous studies on
children (not adults) had claimed an association in com-
pletely the opposite direction [21–23].
Despite these isolated signiﬁcant discrepancies, the sum-
mary ROR estimate across all 93 associations was 0.96 (95%
CI, 0.91–1.01) showing high overall agreement. There was no
heterogeneity across the ROR estimates across the 93 probed
associations beyond what would be expected by chance alone
(I
2¼0). Several studies had wide 95% CIs. Such studies would
tend to increase the degrees of freedom and thus may hide
some between-study heterogeneity. Analyses strictly limited
to the exact same ‘‘ethnic’’ groups in both types of design
yielded an identical summary ROR estimate of 0.96 (95% CI,
0.91–1.01), and again there was no heterogeneity between the
93 ROR estimates.
Although the differences in the results of the two designs
were rarely nominally signiﬁcant, the exact point estimates of
the OR
F and OR
U often differed substantially. In 26
comparisons (28%), the two designs estimated effects in the
opposite direction (one above 1, the other below 1). In 64
comparisons (69%), the relative risk increase (OR 1) of the
unrelated case-control design was less than half or more than
double compared to the family-based design.
We further examined the concordance in the level of
nominal statistical signiﬁcance, i.e. whether both designs
found signiﬁcant or non-signiﬁcant results at the p ¼ 0.05
level of signiﬁcance. We estimated the probability that the
unrelated case-control design gives a signiﬁcant result and
family-based gives a non-signiﬁcant result, and the proba-
bility of the inverse scenario. These probabilities of opposite
classiﬁcation were 14% (95% CI, 8%–23%) and 17% (95% CI,
10%–27%), respectively.
Subgroup Analyses
In theory, the design, conduct, and reporting of the two
types of studies may inﬂuence the degree to which they agree.
Therefore, we examined whether the results obtained with
the two types of designs were more or less likely to differ
systematically when there were overlapping populations in
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Synopsis
Different types of designs are used for the assessment of genetic
associations for complex diseases. Case-control studies of unrelated
people and family-based designs are the most widely used. Each has
its advantages and disadvantages. This paper compares the
estimates of the two types of design using a meta-analytic
approach, i.e. a systematic selection of data and quantitative
synthesis of results across many studies. The authors examined 93
associations where both unrelated case-control and family-based
designs had been employed. Both designs gave overall similar
estimates of association and the conclusions were very similar in
subgroup analyses that considered various design features that
might affect in theory the degree of agreement between the two
designs. No heterogeneity between studies was observed. Hence,
there was no consistent pattern of over-estimation or under-
estimation of the probed association with one or the other design.
However, one cannot exclude the possibility that rare large
differences or common small differences may occur between the
two designs.the two designs; when one design had clearly been applied
ﬁrst; when studies claimed to be the ﬁrst article on the
probed association; when results were presented based on the
statistical signiﬁcance of their ﬁndings or the ﬁndings of the
other design; when there was violation of or major deviation
from HWE in the unrelated controls; or when we had selected
only one association among many presented in an article;
when the sample size of unrelated case-controls contained
more that 1,000 alleles; and when TDT studies used families
with multiple affected sibs or not. There was no suggestion
that these characteristics inﬂuenced systematically the overall
summary ROR in the respective subgroup analyses (Table 2).
Deviation of Genetic Effect Estimates as a Function of the
Amount of Data
The ROR estimate is expected to ﬂuctuate more around 1,
when the data obtained by either design are more limited.
Figure 2 shows the relative deviation of the two designs (ROR
estimates coined to be always  1) as a function of their
summary standard error. With a standard error of 0.29 (the
median standard error observed in these 93 association
datasets), on average, it is expected that the two OR estimates
deviate on average 1.27-fold (95% CI, 1.00–1.66). When the
standard error is halved (0.145), on average the two OR
estimates are expected to deviate only 1.12-fold (95% CI,
1.00–1.37). Nevertheless, this is just an average estimate and
some points, especially among the smaller studies, did not ﬁt
very well to this regression.
Discussion
Unrelated case-control and family based-designs gave
overall similar estimates of association. This means that there
was no consistent pattern of over-estimation or under-
estimation of the probed association with one or the other
design. One might wonder whether family-based studies give
much larger estimates than unrelated case-control studies in
some occasions, and much smaller estimates in other
occasion, but on average these differences cancel out.
However, the absence of heterogeneity that we observed
does not support this claim. Our analyses were more
consistent with the interpretation that typically there is
agreement in the estimates obtained by the two designs. Our
ﬁndings should be interpreted cautiously given the small
sample sizes in several of these studies.
Considerable differences in the OR point estimates
between the two types of design are common and they reﬂect
mostly the uncertainty that accompanies the estimates of
small studies. If inferences are made categorically for the
presence or not of formal statistical signiﬁcance, discrep-
ancies between the two study designs are common and the
same applies, when inferences are made based on the
magnitude of the point estimates of the genetic effects, if
the uncertainty thereof, is ignored. Power deﬁcit is a major
concern for small studies and this is a greater concern for
family-based designs [24], where getting sufﬁciently large
numbers of pedigrees is not easy. While ingenious designs
may improve efﬁciency [25] making claims for the presence
or absence of an association with sparse data would be
precarious with either study design. This is a major concern
currently as whole genome association approaches are
performed and investigators may try to employ both designs
in the discovery and replication process [26]. With small
sample sizes, many important genetic variants may be missed.
Most of the pursued genetic associations are likely to have
ORs in the range of 1.2–1.6 [4]. Given the sample sizes used in
genetic association studies to-date, the average chance
deviations in the estimated effects between the two designs
are well in this range. Unless sample sizes increase, true
signals may be buried in the noise due to chance. Simulation
studies in high-throughout situations also concord that
unrelated case-control designs are very powerful compared
with the more laborious family-based collections [27].
We should acknowledge that with large studies of many
thousands of cases and controls, even modest stratiﬁcation
problems may yield spuriously formally statistically signiﬁ-
cant results. Since most genome-wide approaches use formal
signiﬁcance rather than effect sizes to select genes for further
testing, modest errors could create considerable problems.
Therefore our ﬁndings should not be interpreted as evidence
that unrelated case-control studies may be designed without
careful standards and proper attention regarding the recruit-
ment of the study population. Furthermore, although not
common, confounding of substantial magnitude may occur
sometimes even within so-called ‘‘racial’’ or even ‘‘ethnic’’
descent groups. This would not be captured by our analyses.
With such confounding, even careful matching at the
ethnicity level would not sufﬁce. Our analysis suggests that
large confounding effects are not common, but we cannot
rule out rare large confounding effects or common small
confounding effects. The latter could still bias well-powered
studies using small alpha levels, a situation that is increasingly
demanded in current genome wide association studies.
We should also caution that some researchers may
preferentially report associations that show similar and
conﬁrmatory results with the two designs. However, our
protocol excluded upfront studies where such selection was
stated to have been applied. We cannot exclude the
possibility that an investigator may be less likely to publish
studies that found very different results in the two types of
design, whereas two independent investigators may not have
the same problem. Unfortunately, by default, unpublished
data cannot be retrieved to see how and to what extent they
might inﬂuence our conclusions. Selection choices may not
be stated at all in the published reports. This publication bias
would tend to increase concordance in the examined sample
of investigations. However, publication bias may also
decrease the overall observed concordance, if some studies
with highly concordant, but ‘‘negative’’ results with both
designs are not published [28].
We also performed subgroup analyses considering a wide
range of other more subtle selection features that may in
theory affect the extent of agreement between the two
designs. Reassuringly, the two designs gave consistent results
in all subgroup analyses. Finally, it is possible that discrep-
ancies may be greater when the two designs have been
applied by different teams of investigators. However, this
concern would apply also to studies with the same design
performed by different investigators.
Overall, our analysis suggests that despite the dangers of
population stratiﬁcation [29,30], on average, unrelated case-
control designs give similar results to family-based designs. Of
note, none of the 93 unrelated case-control studies analyzed
here had used genomic control or other proposed methods
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Family-Based versus Case-Control StudiesTable 1. Evaluated Comparisons of Family-Based versus Unrelated Case-Control Designs
ID Gene
(Polymorphism)
Outcome Overlapping
Populations
Design
Performed
First
First Study
on the
Association
HWE Violation
or Major
Deviation
Selection of
Presented
Data
SNPs with
Full Data for
Both Designs
1 CRTH2 (G1544C) Asthma þ fb þ No   2
2 CCK (C to T) Schizophrenia þ cc   No   1
3 MLC1 (rs2076127 G/A) Schizophrenia þ    NA þ 8
4 5-HT2c (Cys23Ser) Anorexia nervosa þ    No   1
5 FMR1 (IVS10þ14C-T) Autism þ    No   1
6 RGS4 (SNP1 A/G) Bipolar disorder þ    No   4
7 Fca ˜R1a ˆ (Gly237Glu) Atopic asthma þ    No   1
8a ˆ3-AR (Trp64Arg) Obesity þ    NA   1
9 GABRG2 ( 158C.T) Febrile seizures þ    No   3
10 LMP2 (R60H G/A) Vitiligo þ    No   8
11 MLC1 (rs2235349 A/G) Bipolar disorder þ    NA þ 8
12 PAI-1 (4G/5G); 4G Meningococcal disease      No   1
13 COMT (Val158Met) ADHD      No   4
14 a ´-adducin (G460W) Hypertension      No   1
15 CTLA4 (49 A/G) Diabetes (type 1)      F(abs) .0.03   1
16 TNF (þ851 A/G) Juvenile oligoarthritis þ cc þ NA þ 4
17 UGRP1 (G112A) Asthma      No   1
18 NTRK2 (rs1187327 G/A) Child mood disorders      No   3
19 RGS4 (SNP1 A/G) Schizophrenia þ    No   4
20 IFNGR1 ( 56T/C) Cerebral malaria þ cc   No þ 2
21 ARNT (567G/C) Oral clefts þ fb þ No þ 2
22 IL4R (Ile50Val) Asthma þ    No   1
23 IFNG (þ874A .T) Tuberculosis   cc þ No   1
24 LMP7 (A or B) Graves disease      NA   2
25 5q31 (C2063G) Crohn disease þ    No   1
26 GNB3 (C825T) Hypertension      No   1
27 a ˆ3-AR (Trp64Arg) Anorexia þ    NA   1
28 5-HTT (5-HTTLPR ins/del) ADHD þ    NA   1
29 VDR (FokI) Tuberculosis      No   4
30 NRG1 (A38G) Schizophrenia      No   1
31 HNF4a ´ (rs2144908 A/G) Diabetes (type 2)      No   2
32 IL-4 ( 590C/T) Atopic dermatitis þ fb   No þ 1
33 CTLA4 ( 318C/T) Hashimoto thyroiditis      NA   1
34 SLC4A3 (2600G/A) Idiopathic epilepsy þ    No   1
35 IL-10 (C 592A) RSV þ    No   1
36 CAPN10 (4841T/C) Diabetes (type 2) þ    NA   4
37 NOTCH4 (SNP1 G/T) Schizophrenia      NA   2
38 DCC (nt 601C .G) Diabetes (type 1)      NA   1
39 5-HTT (5-HTTLPR L/S) Childhood depression þ    No   1
40 5q31 (C2063G) Ulcerative colitis þ    No   1
41 CTLA4 ( 318C/T) Graves disease      NA   1
42 ADAM33 (Fþ1 G/A) Asthma      NA   15
43 CD14 (C159T) Asthma      No   1
44 ENPP1 (K121Q) ESRD þ cc   NA   1
45 COMT (High/Low Activity) Kleine-Levin syndrome þ    No þ 1
46 NFKB1 ( 94ins/delATTG) Ulcerative colitis   fb þ No   1
47 ZDHHC8 (rs175179 A/G) Schizophrenia þ cc   No   2
48 CTLA4 (þ49 A/G) Celiac disease      No   1
49 IL12B (1188 A/C) Celiac disease      NA   1
50 HOXA1 (A218G) Autism þ    No   1
51 MMP3 (rs4754884 A/G) Ankylosing spondylitis      NA   8
52 ESR1 (T29C) HBV þ cc   Yes þ 1
53 COMT (Val158Met) Anorexia      No   1
54 IL-4 ( 589C/T) Asthma and atopy þ    No þ 3
55 HTR1B (G861C) Schizophrenia   cc   No   1
56 MTHFR (C677T) IGR þ    No   4
57 LYP/PTPN22 (1858C.T) Diabetes (type 1)      No   1
58 NFKB1 ( 94ins/delATTG) Celiac disease þ fb þ No   1
59 IL-8 ( 251T .A); T Tuberculosis   cc þ NA þ 1
60 CAPN10 (4852G/A) Polycystic ovaries    þ No   4
61 CC16 (A38G) Asthma      No   1
62 SPINK1 (N34S) Pancreatic diabetes þ fb   No   1
63 IL-4 (C 590T) RSV bronchiolitis þ    No   3
64 DRD2 ( 141C/ A ¨C) Schizophrenia      No   1
65 CAPN10 (SNP 43 G/A) Obesity þ    No   1
66 TLR4 (Asp299Gly) Asthma þ    No   1
67 CTLA4 (MH30G/C) Diabetes (type 1) þ    NA   4
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danger of population stratiﬁcation. However, this average
agreement does not decrease the need to design and conduct
these studies very carefully and to take all the necessary steps
to avoid bias. Bias with resulting discrepancies may manifest
with either false positives or true positives with biased effect
estimates. Bias could be due to suboptimal population
sampling, phenotype misclassiﬁcation, genotyping error,
confounding due to other sources, poor matching or over-
matching, and selective reporting [2,31,22]. Most of these
problems apply also to family-based designs [33], so these
studies should not be considered immune to bias.
Allowing for these caveats, both types of design can yield
useful and complementary information. Methods to improve
efﬁciency of design and combination of data from both
designs are welcome [12–16] and such methods should be
tested more widely in the ﬁeld. The applicability of methods
of adjustment for population stratiﬁcation also needs further
empirical study [6–11]. However, the main problem appa-
rently is not the lack of concordance between family-based
and unrelated case-control studies, but the large uncertainty
accompanying the estimates of small studies with large
standard errors. Small studies are likely to suffer also more
biases and may be more prone to selective reporting and
publication bias [34–37]. Increasing the sample size of the
available evidence should be a priority in complex disease
genetics [31]. Large-scale studies and collaborative enter-
prises [38,39] should consider both types of designs, and may
help reduce the replication uncertainty for genetic associa-
tions.
Materials and Methods
Eligible studies and search strategy. We considered published
studies that examined genetic associations for the same polymor-
phisms using both family-based and unrelated case-control designs in
the same article. Eligible studies were those where we could extract or
compute the allele-based log-odds ratio and its variance for at least
one association with a phenotype that had been probed with both
designs. For consistency, we focused on biallelic markers and binary
phenotypes. We excluded studies where data had been obtained for
many genetic markers and/or phenotypes, but the results had been
selected for presentation based on the concordance of the two
designs. We excluded studies considering microsatellites, non-
biallelic markers and continuous traits; and non-English language
articles.
We searched PubMed using the terms ‘‘transmission disequili-
brium test,’’ ‘‘TDT,’’ ‘‘STDT,’’ ‘‘PDT,’’ ‘‘Sib-TDT,’’ ‘‘ETDT,’’ ‘‘RC-
TDT,’’ or ‘‘family based,’’ combined with the terms ‘‘unrelated’’ or
‘‘case-control.’’ The search was last updated on 31 July 2005, and
2,151 items were retrieved and screened for eligibility: 1,993 could be
excluded from inspecting the title and abstract, and 158 were
examined in full-text for eligibility. A total of 84 articles were eligible;
one gene-phenotype association was systematically selected for each
of them, except for nine articles where two very different phenotypes
were addressed.
For eligible reports, when data were available for the comparison
of the two designs for two or more polymorphisms, we selected the
one that was ﬁrst mentioned in the text. We set this rule to avoid
subjectivity in the selection of the polymorphism to be analyzed and
to avoid having many correlated data stemming from the same
compared study groups. When two or more entirely different
Table 1. Continued
ID Gene
(Polymorphism)
Outcome Overlapping
Populations
Design
Performed
First
First Study
on the
Association
HWE Violation
or Major
Deviation
Selection of
Presented
Data
SNPs with
Full Data for
Both Designs
68 GRIK2 (intron 14 C/T) OCD þ  þ No   4
69 CTLA-4 (49A/G) Graves disease   cc   No   1
70 MTHFR (C677T) Spina bifida þ    No   1
71 ALOX5AP ( 336G/A) Asthma þ  þ No   1
72 CCR2 (c.190G.A) Sarcoidosis þ    No   3
73 LILRA3 (wild/deletion) Celiac disease þ  þ F(abs).0.03   1
74 SSADH (CAC(H)538CAT(Y)) High IQ   cc   No   1
75 TP53 ( 1863C/T) Schizophrenia      NA   8
76 ENPP1 (K121Q) Proteinuria þ cc   NA   1
77 MOG (C1334T) Schizophrenia þ    No   2
78 CAPN10 (SNP 43 G/A) Diabetes (type 2)      NA   4
79 PAFAH (Val279Phe) Asthma þ    No   1
80 NMDAR2B (G2108A) Alcoholism þ    No   2
81 DRD1 (rs4532C) ADHD þ    NA   17
82 COMT (Val158/108Met) Schizophrenia þ    No   1
83 HTR4 (SVRSNP1 C/T) All mood disorders   cc   Yes, F(abs).0.03 þ 2
84 ADCYAP1 (g.9863G.A) Diabetes (type 2)   fb þ No   1
85 HTR4 (SVRSNP1 C/T) Schizophrenia   cc   Yes, F(abs).0.03 þ 2
86 NOTCH4 (SNP1 G/A) Schizophrenia      No   2
87 CCR5 (wt/Delta32) Asthma þ fb   No   1
88 TNFSF5 ( 726T/C) Tuberculosis   fb þ No þ 1
89 GABBR1 (A 7265G) Schizophrenia    þ No   5
90 TIM1 (rs2277025 C/T) Asthma þ cc   No   7
91 NDUFV2 ( 3542G.A) Bipolar disorder    þ No   6
92 DBH (TaqI) ADHD þ  þ NA   1
93 CCR5 (wt/Delta32) Asthma þ fb   No   1
The gene and polymorphism nomenclature follows the conventions used in each examined investigation.
ADHD, attention-deficit hyperactivity disorder; cc, unrelated case-control; ESRD, end-stage renal disease; F(abs), absolute fixation coefficient; fb, family-based; HBV, hepatitis B virus; IGR,
intrauterine growth restriction; IQ, intelligence quotient; NA, not available; OCD, obsessive compulsive disorder; RSV, respiratory syncytial virus.
DOI: 10.1371/journal.pgen.0020123.t001
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Family-Based versus Case-Control StudiesFigure 1. ROR and 95% CIs for Each Comparison of an Unrelated Case-Control Study versus Family-Based Study
Odds ratios have been coined in such a way so that the summary OR of the two designs would be .1. Also shown are the summary ROR and its 95% CIs
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Family-Based versus Case-Control Studiesphenotypes were examined in the same article, we considered each
one of them separately.
Databases. We recorded the numbers in the 2 3 2 table of each
analyzable unrelated case-control design for an allele-based analysis
(only this would be feasible for the family-based designs). The OR
U
was estimated as the ratio of the products of the two diagonals and
the variance of its natural logarithm was estimated by the sum of the
inverse of the four cells of the 2 3 2 table. We also recorded the
number of transmitted (T) and non-transmitted (NT) alleles in the
respective family-based design. The OR
F was estimated as the ratio of
T over NT and the variance of its natural logarithm was estimated by
the sum 1/T þ 1/NT. For studies where this information was not
directly available, we extracted information in order to calculate OR
F
and OR
U from other presented data (p-values, chi-square statistics,
number of informative transmissions, proportion transmitted, odds
ratio and 95% CIs). OR estimates were ﬁrst derived for the minor
versus major allele.
In 18 studies that had used data from people of different ‘‘racial/
ethnic’’ descent, the OR was estimated ﬁrst in each ‘‘racial/ethnic’’
subgroup and data were then combined for each design across the
available ‘‘racial/ethnic’’ subgroups using stratiﬁed analyses (Mantel-
Haenszel method) to obtain a single OR estimate per design.
Summary OR and ROR. Suppose the frequency of alleles in cases
and controls in the unrelated case-control study are f 1
A;f 1
a and f 0
A;f 0
a
respectively. Taking allele a as the risk allele, the odds ratio of disease
risk can be estimated by ORU ¼
f 1
a f 0
A
f 1
Af 0
a. The standard error of the natural
logarithm of OR is estimated by SE
U ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
f 1
A
þ 1
f 1
a þ 1
f 0
A
þ 1
f 0
a
q
. For TDT
studies, if T is the number of transmitted high risk alleles and NT the
umber of non-trasmitted alleles the odds ratio of disease risk can be
estimated by ORF ¼ T
NT. The standard error of the natural logarithm
is estimated by SE
F¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
T þ 1
NT
q
.We combined the OR
F and OR
U for the
minor allele for each association in order to obtain a summary OR.
This summary OR was estimated as the weighted sum of the ORF and
OR
U using the natural logarithms of the two ORs and their inverse
variances as weights. For consistency, all summary ORs were then
coined to be  1.00. This means that when the summary OR was ,1
using the minor versus major allele contrast, then we used the major
versus minor allele contrast instead for both the unrelated case-
control and family-based data. The purpose of coining the summary
OR to be  1.00 was to make this metric show consistently the
strength of the association, regardless of whether the minor allele
might be protective or conferring susceptibility. This allowed to
evaluate whether unrelated case-controls consistently suggests a less
strong gene-outcome association compared to family-based designs
or vice versa.
The ratio of the OR
U and OR
F was calculated to obtain the ROR
[26] for each probed association according to the allele contrast that
yielded summary OR  1.00. The variance of the natural logarithm of
the ROR is the sum of the variances of the natural logarithms of OR
F
and OR
U.
The natural logarithms of the ROR estimates were combined to
obtain the summary ROR [40,41] using ﬁxed and random effects
calculations [42,43]. In ﬁxed effects calculations it is assumed that the
true effect of risk allele is the same value in each study, whereas in
random effects calculations the risk allele effects for the individual
studies are assumed to vary around some overall average effect.
Between-study heterogeneity in the ROR estimates was quantiﬁed
with the I
2 statistic which is calculated by I
2¼100%(Q df)/Q, where Q
is the Cochran’s heterogeneity statistic and df the degrees of freedom
[44]. I
2 ranges between 0% and 100% and estimates the amount of
heterogeneity that is beyond chance. Heterogeneity is considered
low, moderate, large and very large for I
2 values of 1%–24%, 25%–
49%, 50%–74%, and 75% or higher, respectively. In the absence of
any heterogeneity, ﬁxed and random effects estimates coincide.
Measures of agreement and disagreement of the two types of
design. The main analysis examined whether the summary ROR is
different from 1. The summary ROR provides an estimate of the
average deviation between the odds ratios in the two study designs,
i.e. whether studies with unrelated case-controls provide consistently
stronger (ROR .1) or consistently weaker (ROR ,1) associations
than family-based studies. In addition, we evaluated whether, for
speciﬁc studies, the 95% CIs of the ROR excluded 1, meaning that the
results of the two types of design differed beyond chance at p ¼ 0.05
level of signiﬁcance.
Identifying a statistically signiﬁcant difference does not depend
only on the magnitude of the difference, but also on the power of the
compared study designs, since very small studies may give very
different point estimates, but with very large uncertainty. Therefore,
we also evaluated whether the OR
F and OR
U were in the same
direction (both above 1 or both below 1) and whether the magnitude
Table 2. Summary RORs in Various Subgroups
Characteristic Subgroup Study Summary ROR (95% CI) I
2 (%)
Overlapping populations No overlap 40 0.97 (0.90–1.04) 0
Overlap 53 0.95 (0.88–1.03) 6
Study design performed first Unrelated case-control 15 1.05 (0.92–1.18) 0
Family-based 10 1.03 (0.82–1.30) 32
Unclear 68 0.94 (0.88–0.99) 0
First study probing association No 77 0.94 (0.89–1.00) 0
Yes 16 1.08 (0.91–1.28) 19
HWE assessment HWE compliance 65 0.95 (0.90–1.01) 0
HWE deviation 5 1.07 (0.86–1.34) 14
HWE not assessed 23 0.95 (0.86–1.06) 1
Results presented based on the statistical significance
of their findings or the findings of the other design
No 80 0.96 (0.91–1.02) 0
Yes 13 0.93 (0.78–1.12) 29
Many associations listed in the same article Yes (one selected for our analysis) 38 0.96 (0.87–1.06) 21
No 55 0.96 (0.90–1.03) 0
Sample size of unrelated case-control studies .1,000 alleles 39 0.95 (0.89–1.01) 0
 1,000 alleles 54 0.98 (0.89–1.08) 10
Number of affected offspring One 74 0.95 (0.90–1.01) 0
Multiple affected offspring 4 0.89 (0.72–1.09) 0
One or more affected offspring 15 1.00 (0.91–1.13) 12
Summary ROR estimates are obtained with random effects calculations. Fixed effects are either identical (when I
2 ¼ 0) or very similar.
DOI: 10.1371/journal.pgen.0020123.t002
(diamond). Size of the boxes represents the weight of each study i which is calculated by wi ¼ 1
SEðRORiÞ
2. ID numbers correspond to Table 1. The crosses at
the end of bars mean that the 95% CI extends beyond the shown range.
DOI: 10.1371/journal.pgen.0020123.g001
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Family-Based versus Case-Control Studiesof the relative risk increase (OR 1) of the unrelated case-control
design was less than half or more than double compared to the
family-based design. Differences in direction are important for
inferences, but estimates in the opposite direction may still be very
close and not incompatible with each other. The OR 1 comparison
focuses on the magnitude of the difference, but does not address its
statistical signiﬁcance. Finally, we evaluated differences in the level of
formal statistical signiﬁcance, i.e. what is the probability that one
design might give non-signiﬁcant results, when the other design gives
signiﬁcant results at the 0.05 level of signiﬁcance. These comple-
mentary approaches have been previously used in the comparison of
effect sizes from different studies in the medical sciences [43,45,46].
Subgroup analyses. We recorded whether one design had clearly
been applied ﬁrst and the other was performed at a second stage. We
also recorded various characteristics that may inﬂuence the observed
concordance between the two types of designs. We noted whether
there was any stated overlap between populations for each design and
whether this was claimed to be the ﬁrst article on this association. In
theory, concordance may be larger when there is overlap in
populations and ﬁrst studies may also be biased towards presenting
concordant results. Moreover, we recorded whether results were
generated or selected for presentation based on their statistical
signiﬁcance, or the signiﬁcance of the results of the other design; in
theory, concordance may then be smaller due to regression to the
mean and the winner’s curse phenomenon [47]. We recorded whether
the distribution of genotypes of the unrelated controls showed
signiﬁcant deviation from HWE based on an exact test and whether
there was large deviation (ﬁxation coefﬁcient .0.03 in absolute value)
[48] regardless of the statistical signiﬁcance of the deviation. The
ﬁxation coefﬁcient is calculated by
F ¼ PAA=pA þ Paa=pa   1
where PAA and Paa are the proportions of the homozygotes and pA and
pa are the proportions of the corresponding alleles. The coefﬁcient
takes values from 1 to 1 depending on the extent of excess or deﬁcit
of homozygotes compared with the proportions expected under the
Hardy-Weinberg law [48]. We ﬁnally recorded large unrelated case-
control studies (.1,000 alleles) and family-based studies including
multiple affected offspring. All of these characteristics were evaluated
in subgroup analyses where the summary ROR was estimated
separately for studies fulﬁlling or not each of these characteristics.
Regression. We examined with a linear regression, the dependence
of the absolute value of the natural logarithm of the ROR on the
standard error of the summary ROR (square root of the variance).
The regression shows the magnitude of the absolute deviation in the
OR estimates obtained with the two designs as a function of the
amount of data. Although there is a certain amount of structural
correlation between ROR and its standard error, this would not affect
considerably the slope and 95% CIs for the regression.
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